摘要
目的研究重组人白细胞介素12真核表达基因(pEGFP-C1_IL-12)在体内外的抗肿瘤作用。方法将pEGFP-C1_IL-12基因转染入体外培养的肝癌细胞HepG_2,MTT法检测肝癌细胞的增殖能力,半定量PCR法检测肝癌细胞血管内皮生长因子(VEGF)的表达情况。进一步经动脉导入重组基因至VX_2移植性肝癌组织,观察与化疗栓塞联合应用时在体内对VX_2肝癌的生长的影响。结果在体外实验中,肝癌细胞的增殖能力及VEGF表达与对照组相比无显著性差异。在体内,基因治疗与化疗栓塞联合应用时,肿瘤生长速度明显减慢。结论重组基因pEGFP-C1_IL-12在体外并不表现出抗肿瘤作用,但在体内抗肿瘤作用明显,这种抗肿瘤作用可能并非重组基因表达产物的直接作用,可能是由间接途径介导的。
Objective To study the anti-tumor effect of a recombinant plasmid expressing human interleukin-12 （pEGFP-C1_IL- 12） in vivo and in vitro. Methods We transduct the recombinant gene （pEGFP-CI_IL-12） to liver cancer cell HepG2 in vitro, and detect reproductive activity of the cell using MTT and the activity of expressing vascular endothelial growth faetor（VEGF） using semiquantitative PCR. And then, we deliver the gene to rabbit liver tumor tissue intraarterial and combine with chemoembolization to observe the antitumor effect to VX2 tumor in vivo. Results There are no statistical difference compared with control group in activity of reproductive and expressing VEGF in vitro. In vivo, tumor growth rate significantly reduce in gene therapy combined with chemoembolization group. Conclusion Recombinant gene （pEGFP-CI_IL-12） exhibit significant anti-tumor effect in vivo but not in vitro, perhaps the anti-tumor effect is associated with an indirect pathway instead of a direct pathway.
出处
《影像诊断与介入放射学》
2010年第1期3-5,共3页
Diagnostic Imaging & Interventional Radiology
基金
国家自然科学基金(30400108)
国家863计划项目(2006AA03Z332)
